Results 211 to 220 of about 6,006,054 (377)

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

Enhanced CYP2C19-mediated drug-drug interaction risk with escitalopram in geriatric populations. [PDF]

Front Pharmacol
Byoun S, Heo DG, Lee M, Lee R, Li Y, Lee JY, Hong E, Lee W.   +7 more
europepmc   +1 more source

Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity

Molecular Oncology, EarlyView.
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung, David Bickel, Lena C. M. Krause, Daria Ezeriņa, Christian Ickes, Julian Wojtachnia, Christine S. Gibhardt, Magdalena Shumanska, Khadija Wahni, Andrea Paluschkiwitz, Julia Malo Pueyo, Ekaterina Baranova, Wim Vranken, Hedwig Stanisz, Ioana Stejerean‐Todoran, Michael P. Schön, Joris Messens, Ivan Bogeski   +17 more
wiley   +1 more source

Drug-Drug Interaction Liabilities with BTK Inhibitor TL-895. [PDF]

Cancer Res Commun
Stromatt JC, Ahmed EA, Drabison T, Nepal MR, Chowdhury AT, Orwick SJ, Buelow DR, Eisenmann ED, Huang KM, Sparreboom A, Baker SD.   +10 more
europepmc   +1 more source

Clinical Pharmacokinetics of Zanisamide and Drug Interaction with Other Anticonvulsants.

, 1994
Yoshio Ijiri, Kazuhide Ohi, Kaoru Suzuki, EISUKE FUKUOKA, TOMOHIRO FURUYA, SHORO YOSHINARI, Hiroshi Tamai   +6 more
openalex   +2 more sources

Drug-drug interactions in the hospital [PDF]

, 2007
Priska Vonbach
openalex   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Contrastive learning-based multi-mechanism disentangled assessment for drug-drug interaction. [PDF]

BMC Bioinformatics
Zhang J, Zeng Y, Tang C, Zhong C, Wen H, Liu Y.   +5 more
europepmc   +1 more source

Pharmacogenetics of drug-drug interaction and drug-drug-gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6.

Pharmacogenomics (London), 2017
M. Bahar, D. Setiawan, E. Hak, B. Wilffert   +3 more
semanticscholar   +1 more source